TANNENBAUM RENEE P 4

What Happened
Renee P. Tannenbaum, a director of Cardiff Oncology, received an award/grant of 40,565 shares on June 11, 2026. The grant is reported at $0.00 per share (a non‑purchase equity award/derivative), so no cash was paid by the insider in this transaction. This is a compensation/award event rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Filing date (Form 4): 2026-06-15 (appears to be filed late vs. the usual 2-business‑day Form 4 requirement).
• Transaction type/code: A = Award/Grant (derivative securities).
• Shares awarded: 40,565; reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the information provided in this summary.
• Notable footnotes: None disclosed in the provided transaction details (no 10b5-1, tax‑withholding, or cashless sale noted).

Context and investor note: Awards reported at $0 generally reflect company compensation (e.g., restricted stock or RSUs) and may be subject to vesting or other conditions; they do not by themselves signal an insider buying stock on the open market. The late filing may be administrative but is worth noting for compliance transparency.